Table 3.

In vivo toxicity and antitumor activity: 5-d schedule

TreatmentNadir body weight (% day 0)ToxicityMedian time to RTV4 (range), dTumor growth delay% Enhancement
Saline p.o., i.p.980/209 (7–13)
TMZ (68 × 5)950/2028 (25–29.5)19.0
TMZ (68) + AG14447 (0.05) (698)890/533 (29–100)24.026.32*
TMZ (68) + AG14447 (0.15) (698)900/558 (43–100)49.0157.89
TMZ (68) + AG14447 (0.5) (698)861/5100 (79–100)91.0378.95
TMZ (68) + MS AG14644 (0.15)940/532 (31–43.5)23.021.05*
TMZ (68) + MS AG14644 (0.5)891/547 (41.5–57.5)38.0100
TMZ (68) + AG14361 (1.5)910/552 (39–96.5)43.0126.32
TMZ (68) + AG14361 (5)960/2051 (46.5–58)42.0121.05
TMZ (68) + AG14452 (5)940/544 (36.5–55)35.084.21
  • NOTE: Insert mesylate salt as for previous tables.

  • * P < 0.05 By Mann-Whitney analysis.

  • P < 0.005.

  • P < 0.0005.